Ether (ETH) spot exchange-traded funds (ETFs) experienced a combined net outflow of $72.544 million on October 8, continuing an eight-day streak of withdrawals. BlackRock's ETHA ETF led the outflows with $71.1208 million withdrawn, though it still holds a strong cumulative net inflow of $12.849 billion since launch. On the inflow side, Fidelity's FETH attracted $5.503 million, raising its total net inflows to $2.334 billion, while Morgan Stanley's MSSE added $1.3209 million, totaling $42.679 million cumulatively. Despite recent outflows, total net assets across all Ether spot ETFs remain significant at $15.636 billion, representing 5.17% of Ethereum's market capitalization, with cumulative net inflows since inception reaching $13.316 billion.
Ether spot ETFs net outflows totaled $72.544 million on October 8, continuing an eight-day withdrawal streak. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 09, 2026 11:02 WIB: out of 50 major cryptocurrencies, 14 rose and 35 fell. Notable movers include CAKE at Rp38.538 with a 4.55% decline and a typical hold time of 75 days, SOL at Rp1.978.168 down 4.42%, and AAVE at Rp2.970.006 down 4.33%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
